Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.72 |
| ▸ | METAP2 | P50579 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.50 |
| ▸ | CD38 | P28907 | 1/20 | 0.50 |
| ▸ | CCR1 | P32246 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.50 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29412561 | 1.00 | PARP1 (0.72) | PARP1METAP2MAPTGAAGLO1 | |
| SCHEMBL29400398 | 0.98 | PARP1 (0.70) | PARP1METAP2MAPTGAAGLO1 | |
| SCHEMBL21816896 | 0.98 | PARP1 (0.70) | PARP1METAP2MAPTGAAGLO1 | |
| SCHEMBL5149194 | 0.98 | PARP1 (0.70) | PARP1METAP2MAPTGAAGLO1 | |
| SCHEMBL27945296 | 0.98 | PARP1 (0.70) | PARP1METAP2MAPTGAAGLO1 | |
| Hydrochloric Acid SCHEMBL27648173 | 0.96 | PARP1 (0.68) | PARP1METAP2MAPTGAAGLO1 | |
| SCHEMBL186645 | 0.95 | PARP1 (0.66) | PARP1METAP2MAPTGAAGLO1 | |
| Phenol SCHEMBL7514748 | 0.92 | PARP1 (0.62) | PARP1METAP2MAPTGAAGLO1 | |
| Phenol SCHEMBL28754889 | 0.91 | PARP1 (0.60) | PARP1METAP2MAPTGAAGLO1 | |
| Phenol SCHEMBL1547794 | 0.89 | PARP1 (0.59) | PARP1METAP2MAPTGAAGLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107417671-B | Coumarin derivative containing quinoline substitution, preparation method thereof and application of coumarin derivative on ratio type pH fluorescent probe | 三峡大学 | 2020-04-24 | — | — | CN | claimed |
| EP-3316884-A1 | THERAPEUTIC INHIBITORY COMPOUDS | Lifesci Pharmaceuticals, Inc. (BB) | 2018-05-09 | — | — | EP | claimed |
| CN-105669644-B | A kind of benzimidazole quinoline, preparation method and applications | 三峡大学 | 2018-01-09 | — | — | CN | claimed |
| CN-107417671-A | A kind of coumarin derivative of the substitution containing quinoline and preparation method thereof and the application on Ratio-type pH fluorescence probes | 三峡大学 | 2017-12-01 | — | — | CN | claimed |
| EP-3169325-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | Lifesci Pharmaceuticals, Inc. (BB) | 2017-05-24 | — | — | EP | claimed |
| WO-2017001924-A1 | THERAPEUTIC INHIBITORY COMPOUDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2017-01-05 | — | — | WO | claimed |
| CN-105669644-A | Benzimidazole quinoline derivative and preparation method and application | 三峡大学 | 2016-06-15 | — | — | CN | claimed |
| WO-2016011209-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2016-01-21 | — | — | WO | claimed |
| CN-100405631-C | Full color organic electroluminescent device | SAMSUNG SDI CO LTD (KR) | 2008-07-23 | — | — | CN | claimed |
| CN-1645642-A | Organic light emitting diode and display including the same | YOUDA PHOTOELECTRIC CO LTD (CN) | 2005-07-27 | — | — | CN | claimed |
| CN-1622721-A | Full color organic electroluminescent device | SAMSUNG SDI CO LTD (KR) | 2005-06-01 | — | — | CN | claimed |
| US-10800766-B2 | Quinoline alkenes as cytoprotective agents | NEURODON CORPORATION | 2020-10-13 | — | — | US | disclosed |
| US-10793558-B2 | Quinoline oxadiazoles as cytoprotective agents | NEURODON CORPORATION | 2020-10-06 | — | — | US | disclosed |
| US-10793558-B2 | Quinoline oxadiazoles as cytoprotective agents | NEURODON CORPORATION | 2020-10-06 | — | — | US | disclosed |
| CN-107417671-B | Coumarin derivative containing quinoline substitution, preparation method thereof and application of coumarin derivative on ratio type pH fluorescent probe | 三峡大学 | 2020-04-24 | — | — | CN | disclosed |
| CN-1622721-A | Full color organic electroluminescent device | SAMSUNG SDI CO LTD (KR) | 2005-06-01 | — | — | CN | disclosed |
| WO-1999041239-A1 | B CELL INHIBITORS | NOVARTIS AG (CH) | 1999-08-19 | — | — | WO | disclosed |
| US-4278680-A | Hypoglycaemically and hypolipidaemically active derivatives of phenylacetic acid | BOEHRINGER MANNHEIM GMBH (DE) | 1981-07-14 | — | — | US | disclosed |
| US-4207341-A | Hypoglycaemically and hypolipidaemically active derivatives of phenylacetic acid | BOEHRINGER-MANNHEIM GMBH (DE) | 1980-06-10 | — | — | US | disclosed |
| US-3956420-A | CPOLYOLEFIN COMPOSITION FOR ELECTRICAL INSULATIONFERROCENE, 8-SUBSTITUTED QUINOLINE | DAINICHI-NIPPON CABLES, LTD. (JA) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800766-B2 | Quinoline alkenes as cytoprotective agents | IAPP, NFE2L2, KEAP1 | PARP1 286/4885METAP2 3543/4885MAPT 725/4885 |
| US-10793558-B2 | Quinoline oxadiazoles as cytoprotective agents | IAPP, PRDX5, HMOX1 | PARP1 992/4885METAP2 3721/4885MAPT 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.